Givinostat 8.86mg/ml oral suspension sugar free
NHS hospitals in England used £33,076,116 of indicative cost of Givinostat 8.86mg/ml oral suspension sugar free in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 36.4% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Givinostat 8.86mg/ml oral suspension sugar free: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Givinostat 8.86mg/ml oral suspension sugar free most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Guy's & St Thomas' Nhs Foundation Trust | £5,953,780 |
| Robert Jones & Agnes Hunt Hpl Nhs Trust | £3,212,272 |
| Univ Hpls Bristol Nhs Foundation Trust | £2,575,356 |
| Manchester University Nhs Ft | £2,132,284 |
| Alder Hey Childrens Nhs Foundation Trust | £2,104,592 |
| Cambridge Univ Hosp Nhs Foundation Trust | £1,509,214 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £1,232,294 |
| University Hpls Of Leicester Nhs Trust | £1,107,680 |
| Univ Hpl B/Ham Nhs Foundation Trust | £1,107,680 |
| Leeds Teaching Hpls Nhs Trust | £1,078,010 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.